2024 APPlexus CLL and MCL

CE / CME

APPlexus Hot Topics 2024: Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: June 05, 2024

Expiration: June 03, 2025

Beth Faiman
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Sandra E. Kurtin
Sandra E. Kurtin, PhD, ANP-BC, FAPO

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Presurvey 1: How confident are you in your ability to describe to patients the differences between covalent and noncovalent BTKi in terms of their molecular characteristics, selectivity, clinical data, approved indications, dosing, safety profiles, efficacy, and their respective impact on clinical practice? 

2.

Presurvey 2: According to current guideline recommendations, which of the following patients would be a candidate for an approved noncovalent BTK inhibitor? 

3.

Patient Case: An 82-Yr-Old Man With Relapsed/Refractory MCL



  • 82-yr-old man who was first diagnosed in 2017 with stage IVA MCL

    • Comorbidities: atrial fibrillation, obesity



  • 1L treatment: BR followed by rituximab maintenance, then PD

  • 2L treatment: acalabrutinib → stable disease before PD with pancytopenia and increasing lymphocytosis

  • He is about to start pirtobrutinib therapy but is worried about developing infections such as pneumonia

Presurvey 3: All of the following would be appropriate approaches to manage pneumonia associated with pirtobrutinib EXCEPT which one?

4.

Presurvey 4: Which of the following noncovalent BTK inhibitors are being evaluated in combination with venetoclax in ongoing phase III trials for patients with R/R CLL/SLL?